Notwithstanding, only few bispecific antibodies have been approved and marketed, namely blinatumomab (55), simultaneously targeting B cell CD19 antigen and T cell CD3 antigen against B cell malignancies, and emicizumab (56, 57), targeting coagulation factors IXa and X against hemophilia A. Finally, catumaxomab, approved in Europe for the intraperitoneal treatment of malignant ascites, binds to the epithelial cell adhesion molecule (EpCAM), T cells (via CD3), and to accessory cells, including dendritic cells, macrophages, and natural killer cells through its Fc-fragment (58). Here, EPCAM is linked to hemophilia A.